Torsdag 31 Oktober | 11:08:37 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2025-02-20 08:00 Bokslutskommuniké 2024
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-08 - X-dag ordinarie utdelning ZWIPE 0.00 NOK
2024-05-07 - Årsstämma
2024-02-22 - Bokslutskommuniké 2023
2023-11-22 - Extra Bolagsstämma 2023
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-11 - Årsstämma
2023-04-28 - X-dag ordinarie utdelning ZWIPE 0.00 NOK
2023-02-03 - Bokslutskommuniké 2022
2022-12-02 - Extra Bolagsstämma 2022
2022-08-23 - Kvartalsrapport 2022-Q2
2022-05-24 - X-dag ordinarie utdelning ZWIPE 0.00 NOK
2022-05-23 - Årsstämma
2022-02-23 - Bokslutskommuniké 2021
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-20 - X-dag ordinarie utdelning ZWIPE 0.00 NOK
2021-05-19 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2021-01-28 - Extra Bolagsstämma 2021
2020-09-29 - Extra Bolagsstämma 2020
2020-05-15 - X-dag ordinarie utdelning ZWIPE 0.00 NOK
2020-05-14 - Årsstämma
2019-12-02 - Extra Bolagsstämma 2019
2019-05-14 - Årsstämma
2019-03-12 - Bokslutskommuniké 2018

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorInformationsteknik
IndustriProgramvara
Zwipe är ett teknikbolag. Bolaget är specialiserade inom biometri och kommersialisering av diverse autentiseringslösningar inom områdena betalning, ID och personlig åtkomst. Exempel på produkter innefattar kompatibla accessystem, fingertrycksavläsning samt digital ID-identifiering. Bolaget grundades under 2009 och har idag störst verksamhet inom Nordamerika, Europa och Asien.
2024-10-07 07:10:00

OSLO, NORWAY - 07-Oct-2024 - One of the prominent global leaders in the pharmaceutical industry is currently testing Zwipe Access biometric cards, in collaboration with a trusted partner, with a view to potentially deploy these innovative cards in its operations.

Zwipe AS, a pioneer in biometric technology, offers Zwipe Access cards equipped with an advanced fingerprint sensor. This technology captures the cardholder's fingerprint securely, delivering the highest level of security and privacy available in biometric systems. By ensuring that the biometric data never leaves the card, Zwipe Access provides an unparalleled safeguard against data breaches.

The global pharmaceutical company involved in this testing is dedicated to reimagining medicine, improving, and extending lives. With the deployment of Zwipe Access cards, the company aims to enhance security across its processes and operations.

Robert Puskaric, President and CEO of Zwipe, shared his thoughts on the potential deployment and said, "Securing individual identities is critical in today's landscape of cyber and security threats. Biometric authentication offers a highly secure, reliable method for identity verification. Since biometric characteristics are unique to each person, Zwipe Access Cards prevents the risk of unauthorized access, all while providing a seamless and intuitive user experience."

About Zwipe
Zwipe believes the inherent uniqueness of every person is the key to a safer future. We work passionately across networks of international organizations, industries, and cultures to make convenience safe and secure. We pioneer next-generation biometric card technology for payment, physical and logical access control, as well as identification solutions. We promise our customers and partners deep insight and frictionless solutions, ensuring a seamless user experience with our innovative biometric products and services. Zwipe is headquartered in Oslo, Norway, with a global presence.
To learn more, please visit http://www.zwipe.com/